Follow the people · Insider

SK

Sherry Korczynski

Insider · Chief Commercial Officer · AQST

Sherry Korczynski files insider transactions with the SEC as a chief commercial officer of Aquestive Therapeutics. We hold 2 disclosed purchases and sales filed since 11 June 2024, 1 of them in the last 90 days.

  • Files forAQST
  • Disclosed buys and sells2 in all, 1 in the last 90 days
  • Last disclosure11 September 2026

Positions held

1 post we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 7 June 20249 September 2026Chief Commercial Officer · Aquestive Therapeutics 18 Form 4 lines · source: SEC Form 4

Every transaction

18 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
18 of 18 shown
9 Sep 202611 Sep 2026SEC Form 42 dexercised options overnot a tradeAquestive Therapeutics8,750 sharesdown −7.2%up +0.0%
9 Sep 202611 Sep 2026SEC Form 42 dsold on the open marketAquestive Therapeutics8,750 sharesdown −7.2%up +0.0%
9 Sep 202611 Sep 2026SEC Form 42 dexercised options overnot a tradeAquestive Therapeuticsderivative8,750 sharesdown −7.2%up +0.0%
14 Aug 202617 Aug 2026SEC Form 43 dhad shares withheld for taxnot a tradeAquestive Therapeutics2,714 sharesup +12.5%up +11.4%
8 Jun 20269 Jun 2026SEC Form 41 dhad shares withheld for taxnot a tradeAquestive Therapeutics2,714 sharesup +22.3%up +19.8%
10 Mar 202611 Mar 2026SEC Form 41 dsold on the open marketAquestive Therapeutics15,741 sharesup +13.8%up +11.9%
10 Mar 202611 Mar 2026SEC Form 41 dsold on the open marketAquestive Therapeutics15,741 sharesup +13.8%up +11.9%
9 Mar 202611 Mar 2026SEC Form 42 dwas grantednot a tradeAquestive Therapeutics75,000 sharesup +11.4%up +11.9%
9 Mar 202611 Mar 2026SEC Form 42 dwas grantednot a tradeAquestive Therapeuticsderivative42,500 sharesup +11.4%up +11.9%
9 Mar 202611 Mar 2026SEC Form 42 dwas grantednot a tradeAquestive Therapeuticsderivative42,500 sharesup +11.4%up +11.9%
9 Mar 202611 Mar 2026SEC Form 42 dwas grantednot a tradeAquestive Therapeutics75,000 sharesup +11.4%up +11.9%
14 Aug 202515 Aug 2025SEC Form 41 dwas grantednot a tradeAquestive Therapeutics25,000 sharesup +16.3%up +16.3%
9 Jun 202510 Jun 2025SEC Form 41 dhad shares withheld for taxnot a tradeAquestive Therapeutics2,714 sharesup +35.0%up +33.5%
7 Mar 202513 Apr 2026SEC Form 4402 dwas grantednot a tradeAquestive Therapeuticsderivative67,500 sharesup +80.4%up +14.1%
7 Mar 202511 Mar 2025SEC Form 44 dwas grantednot a tradeAquestive Therapeuticsderivative35,000 sharesup +80.4%up +81.1%
7 Mar 202511 Mar 2025SEC Form 44 dwas grantednot a tradeAquestive Therapeutics90,000 sharesup +80.4%up +81.1%
7 Mar 202511 Mar 2025SEC Form 44 dhad shares withheld for taxnot a tradeAquestive Therapeutics5,428 sharesup +80.4%up +81.1%
7 Jun 202411 Jun 2024SEC Form 44 dwas grantednot a tradeAquestive Therapeutics25,000 sharesup +73.8%up +70.1%

Both percentages are the stock’s move, not Sherry Korczynski’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold11 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 18 of the 18 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.